CompletedNot Applicable

Almitrine in COVID-19 Patients With ARDS Treated by HFNO

France62 participantsStarted 2021-01-01

Plain-language summary

The purpose of this study is to determine the effects of Almitrine administration on oxygenation in COVID-19 patients with acute respiratory distress syndrome treated by high-flow nasal canula oxygen therapy as first-line ventilatory support.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients treated by high-flow nasal canula oxygen
✓. Positive COVID-19 real-time reverse transcriptase-polymerase chain reaction assay in nasal swabs
✓. Persistent severe hypoxemia after awake prone positioning defined by one or more of the following criteria:
✓. SpO2 \< 96% with FiO2 \> 80%
✓. PaO2/FiO2 ratio \< 100 with FiO2 \> 80%
✓. Patients treated by Almitrine

Exclusion criteria

✕. Age \<18 years old and pregnant women
✕. Patients under legal protection
✕. Patients with a do not intubate or do not resuscitate decision
✕. Patients requiring immediate invasive mechanical ventilation
✕. Contraindication to Almitrine
✕. Poor echogenicity

What they're measuring

Almitrine-induced increase in Pa02/FiO2 ratio.

Timeframe: The 30-minute duration of Almitrine bolus

Trial details

NCT IDNCT05216575

SponsorCentre Hospitalier Universitaire de Nice

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-01-31

View on ClinicalTrials.gov More ARDS trials